Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma
SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH). rhTSH has long been approved in several countries to facilitate monitoring and ablation of thyroid carcinoma without hypothyroidism caused by thyroid hormone withdrawal (THW). To assess the safety, tolerance, pharmacokinetic an...
Main Authors: | Yushen Gu, Hongrong Xu, Yanling Yang, Yan Xiu, Pengcheng Hu, Min Liu, Xiangqing Wang, Jun Song, Yan Di, Jian Wang, Xiaoxia Zhang, Tao Xu, Xuening Li, Hongcheng Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.615883/full |
Similar Items
-
Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells
by: Yongzeng Fan, et al.
Published: (2023-01-01) -
Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?
by: Freba Grawe, et al.
Published: (2022-01-01) -
Zdravljenje metastatskega diferenciranega raka ščitnice z radiojodom ob rhTSH
by: Ivana Žagar
Published: (2009-06-01) -
In Vivo Imaging of Thyroid Cancer with <sup>99m</sup>Tc-TR1401 and <sup>99m</sup>Tc-TR1402: A Comparison Study in Dogs
by: Filippo Galli, et al.
Published: (2021-04-01) -
Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study
by: Ji Young Lee, et al.
Published: (2022-12-01)